Skip to Main Content

Author Details

Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
2005
50
25
PMIDPaper TitleJournal TitlePublished Year
36629386Advances in preclinical models of prostate cancer for research discovery.J Endocrinol2023
36650259The future of patient-derived xenografts in prostate cancer research.Nat Rev Urol2023
35869742New approaches to targeting epigenetic regulation in prostate cancer.Curr Opin Urol2022
35413990OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.Sci Rep2022
36923279Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer.Cancer Res Commun2022
33067172Cancer Plasticity: The Role of mRNA Translation.Trends Cancer2021
33620092Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.J Pathol2021
33799802Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment.Cancers (Basel)2021
34413304The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.Nat Commun2021
34413130CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.Mol Cancer Ther2021
34111999High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.SLAS Discov2021
33406413Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.Cell Rep2021
32132214Knowing what's growing: Why ductal and intraductal prostate cancer matter.Sci Transl Med2020
33134178Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer.Front Oncol2020
33094211PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery.J Endocr Soc2020
32571390Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels.Clin Epigenetics2020
32188493Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.Clin Epigenetics2020
30901730Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.Neoplasia2019
31556460Translational offsetting as a mode of estrogen receptor α-dependent regulation of gene expression.EMBO J2019
31212368Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.Prostate2019
31061140Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment.Mol Cell Proteomics2019
28977728Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.BJU Int2018
30049486Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.Eur Urol2018
29650553Enduring epigenetic landmarks define the cancer microenvironment.Genome Res2018
28067867Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Nat Commun2017
28089303Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.Eur Urol2017
28342640Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.Eur Urol2017
28510269Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.Mol Oncol2017
27528024A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.Oncotarget2016
27617737A community-based model of rapid autopsy in end-stage cancer patients.Nat Biotechnol2016
27717381Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling.Genome Biol2016
25154392Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.Eur Urol2015
26177841Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.Prostate2015
26143334Pro-tumorigenic role of ERα in prostate cancer cells.Aging (Albany NY)2015
25436982Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.Oncotarget2015
24464224DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.Cell Death Differ2014
23097118Primary culture and propagation of human prostate epithelial cells.Methods Mol Biol2013
23558784A preclinical xenograft model of prostate cancer using human tumors.Nat Protoc2013
23562048A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer.Biomaterials2013
22597536Long terminal repeats act as androgen-responsive enhancers for the PSA-kallikrein locus.Endocrinology2012
22808245Estrogen receptor β activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations.PLoS One2012
22505522The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness.Biol Chem2012
21656830Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.Prostate2011
20103546Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.Endocr Rev2010
20406994A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells.RNA2010
19147544Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer.Mol Cancer Res2009
17680632Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.J Cell Physiol2007
17587816Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.Cells Tissues Organs2007
16800731The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.Biol Chem2006
16172196Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.Endocr Relat Cancer2005
  • 1 - 50 of 50

Recommended Authors

Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 9
Xinpei Ci
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 5
Estelle Li
University of British Columbia
Career Start Year 2012
Number of shared co-authors 5
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 5
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 13
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 6
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 5
Alastair Davies
University of British Columbia
Career Start Year 2008
Number of shared co-authors 6
Andrew S Goldstein
University of California los angeles
Career Start Year 2008
Number of shared co-authors 2
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 16
Tamara L Lotan
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 9
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 1
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 9
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 6
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 6
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 3
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 7
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 10
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 10
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 7
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 8
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 8
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 6
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 2
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 4
Isla P Garraway
David Geffen School of Medicine University of California Los Angeles
Career Start Year 1993
Number of shared co-authors 5
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 3
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 8
Martin E Gleave
University of British Columbia
Career Start Year 1987
Number of shared co-authors 15
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 8

Collaborators

Gail P Risbridger
Biomedicine Discovery Institute, Monash University
Co-authored papers 38
Renea A Taylor
Peter MacCallum Cancer Centre
Co-authored papers 31
Mark Frydenberg
Monash University
Co-authored papers 16
Melissa Papargiris
Biomedicine Discovery Institute, Monash University
Co-authored papers 12
Judith A Clements
Co-authored papers 11
David Clouston
Co-authored papers 9
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Co-authored papers 8
Damien Bolton
University of Melbourne
Co-authored papers 6
Heather Thorne
Peter MacCallum Cancer Centre
Co-authored papers 6
Luke A Selth
Adelaide Medical School, University of Adelaide
Co-authored papers 5
Richard J Rebello
University of Melbourne
Co-authored papers 4
Kaylene J Simpson
The University of Melbourne, Peter MacCallum Cancer Centre
Co-authored papers 3
Ivan Topisirovic
McGill University
Co-authored papers 3
David Nicol
The Royal Marsden Hospital
Co-authored papers 3
Richard B Pearson
Co-authored papers 2
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 2
Ania Sliwinski
The Sir Peter MacCallum Department of Oncology University of Melbourne
Co-authored papers 2
Eva Corey
University of Washington School of Medicine
Co-authored papers 2
Gillian Mitchell
Familial Cancer Centre Peter MacCallum Cancer Centre Parkville Victoria 0 Australia.
Co-authored papers 2
Arun A Azad
Peter MacCallum Cancer Centre
Co-authored papers 2
Yu-Jia Shiah
Ontario Institute for Cancer Research
Co-authored papers 1
Lawrence E Heisler
Ontario Institute for Cancer Research
Co-authored papers 1
Tim R Mercer
Australian Institute for Bioengineering and Nanotechnology, University of Queensland
Co-authored papers 1
Robert G Bristow
University of Toronto
Co-authored papers 1
Nora M Navone
MD Anderson Cancer Center
Co-authored papers 1
Amina Zoubeidi
University of British Columbia
Co-authored papers 1
Winnie Lo
The Hospital for Sick Children
Co-authored papers 1
Makoto R Hara
Co-authored papers 1
Julia F Hopkins
Foundation Medicine Inc.
Co-authored papers 1
Mark A Rubin
University of Bern
Co-authored papers 1
Release 1.2